HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. - Wikidata - awgldk - TriplyDB

HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells.

HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells.

http://www.wikidata.org/entity/Q44450066

about

LAPTM4B: a novel cancer-associated gene motivates multidrug resistance through efflux and activating PI3K/AKT signaling KIF14 promotes AKT phosphorylation and contributes to chemoresistance in triple-negative breast cancer Dual Inhibitor AEE788 Reduces Tumor Growth in Preclinical Models of Medulloblastoma Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters Overexpression of PIAS3 suppresses cell growth and restores the drug sensitivity of human lung cancer cells in association with PI3-K/Akt inactivation HER2 expression in cervical cancer as a potential therapeutic target New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists Differential responses to doxorubicin-induced phosphorylation and activation of Akt in human breast cancer cells.Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.Targeting of erbB3 receptor to overcome resistance in cancer treatment Breast cancer chemoprevention: old and new approaches Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic Role of Akt signaling in resistance to DNA-targeted therapy PI3K mutations in breast cancer: prognostic and therapeutic implications Molecular imaging of EGFR/HER2 cancer biomarkers by protein MRI contrast agents HER2 confers drug resistance of human breast cancer cells through activation of NRF2 by direct interaction Vandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport function A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics Inhibition of Akt phosphorylation attenuates resistance to TNF-α cytotoxic effects in MCF-7 cells, but not in their doxorubicin resistant derivatives How may targeted proteomics complement genomic data in breast cancer?Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data Responsiveness to PI3K and MEK inhibitors in breast cancer. Use of a 3D culture system to study pathways related to hormone independence in mice.Akt2 inhibition enables the forkhead transcription factor FoxO3a to have a repressive role in estrogen receptor alpha transcriptional activity in breast cancer cells.Her2 activates NF-kappaB and induces invasion through the canonical pathway involving IKKalpha.siRNA-based targeting of cyclin E overexpression inhibits breast cancer cell growth and suppresses tumor development in breast cancer mouse model.Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.COX-2 activation is associated with Akt phosphorylation and poor survival in ER-negative, HER2-positive breast cancer.Therapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myeloma.A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression Sensitization of cancer cells through reduction of total Akt and downregulation of salinomycin-induced pAkt, pGSk3β, pTSC2, and p4EBP1 by cotreatment with MK-2206.The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity Alpha-actinin 4 and tumorigenesis of breast cancer.Shc is required for ErbB2-induced inhibition of apoptosis but is dispensable for cell proliferation and disruption of cell polarity Soft tissue sarcoma cells are highly sensitive to AKT blockade: a role for p53-independent up-regulation of GADD45 alpha.Axitinib targeted cancer stemlike cells to enhance efficacy of chemotherapeutic drugs via inhibiting the drug transport function of ABCG2.Expression of HER-2 affects patient survival and paclitaxel sensitivity in endometrial cancer Lapatinib antagonizes multidrug resistance-associated protein 1-mediated multidrug resistance by inhibiting its transport function.miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer.Development of peptide nucleic acid probes for detection of the HER2 oncogene

P2860

Q24296238-B712E576-044A-4C2D-812C-E70A730F0952 Q24296484-FF00CFFA-CFB9-4B69-A1F3-A5067E052883 Q24615472-8AD68DC2-7A4C-422C-A579-12C9CB7F5A21 Q24617999-A6E67387-94B2-4DD9-AB59-02164612692D Q24678516-D481B1F7-7351-471C-B4B3-2F93BBC2C2B9 Q24792559-62513386-B5C3-4C9F-994D-FAFFAFCEAEE8 Q24806542-469871C6-CD83-4711-9B82-06D79D99CF88 Q24813382-BB302CAC-C5A6-4C3A-83BF-8C54B18620FA Q24813543-CF4552D7-8042-4D1B-A884-EFBF537E0BAA Q26864668-E39CCF71-75A2-456B-B0C0-FB8E5CDCE13C Q27693259-01866967-7BDA-488E-A1A8-B07E527B183F Q27824826-0549A928-D2A3-46BD-B3B6-99FA754CCF04 Q28066950-C9087E4F-2C92-45A8-B9CA-ADB2F1E208D7 Q28081992-68DD57A1-F057-4B8A-B43E-085A6B0A65B3 Q28304646-DE899AA3-E8A6-4D59-8C72-90C26FAFEB3E Q28383407-8FF1D817-6E7A-453F-B4EC-CEBE3D188C91 Q28475378-0914E23B-BFA6-46BC-A406-FD72FAA77F8A Q28477202-FD75E1DD-DF8F-48A4-9843-1EA1D1C0B4DB Q28751743-2CCBE976-D63E-4329-8F53-80062604DDF2 Q28817765-53763002-8955-4D0E-B55A-02826BDF5989 Q31140924-87307FAB-7FAD-4C44-BC1D-352491EA951D Q33388617-404FEF22-CBF6-4346-B1BF-A9BA65F64237 Q33592917-9E663037-BAAF-418A-AC93-D9363E96C892 Q33614071-D6D797ED-FCC4-496B-AD4A-5A1F0D0E8535 Q33690338-3A442868-4D75-437B-B6F7-4912884F7448 Q33705021-D68F1D71-6C12-44F3-AAF3-2D763318F217 Q33709971-803E9D48-2567-46F0-8EC3-CDB97C2DEDCB Q33747000-626E304E-425E-41A2-95D7-10B03003155F Q33934617-D0C46880-8C4F-420F-9191-9072D1ED2BE8 Q33991817-4B8424EF-D34E-4FA7-9059-A005A8B83F7B Q33992871-8D63039C-4C85-4E11-970C-D18DE7AC30DC Q34036041-DBDC55B6-C780-4E3E-B18B-C453CDE38A2E Q34084701-F4A1DD8E-D886-4ACE-9AD9-A857FCD13687 Q34169164-D129148C-FAA7-4E2C-B8A0-D6AF8E89748C Q34240979-1BD45FA4-0FE2-4ACF-AF90-390FE643A012 Q34253081-BFFD15EA-A464-4D3C-9332-DF70D6F6E09B Q34253654-1E9E9504-CF0C-44FD-84B6-CDDE90EBD621 Q34416223-F360F554-741E-4A05-9E3C-36D64CC5988D Q34524533-A1129970-1A9C-4525-B701-167B5668B12B Q34672269-C690D28D-FE22-4518-9A1B-24EACEF47E31

P2860

HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells.

http://www.wikidata.org/entity/Q44450066

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

HER2/PI-3K/Akt activation lead ...... n breast adenocarcinoma cells.

@en

HER2/PI-3K/Akt activation lead ...... n breast adenocarcinoma cells.

@nl

type

label

HER2/PI-3K/Akt activation lead ...... n breast adenocarcinoma cells.

@en

HER2/PI-3K/Akt activation lead ...... n breast adenocarcinoma cells.

@nl

prefLabel

HER2/PI-3K/Akt activation lead ...... n breast adenocarcinoma cells.

@en

HER2/PI-3K/Akt activation lead ...... n breast adenocarcinoma cells.

@nl

P1433

Q44450066-7972F6E9-BDE8-46E1-9678-A83253B63F9F

P1476

Q44450066-15D83B46-6324-46D5-9650-DBBCA316DD49

P2093

Q44450066-10A8B2DC-C453-4A4C-B822-023ECF5D622B

Q44450066-2EB387C6-4049-423A-9E49-456CF44865CC

Q44450066-6C9799C8-2C56-4A29-BEF4-0538993EEAD4

Q44450066-753F17B4-1029-41C9-BF56-8BE2588C808A

Q44450066-7E303B8E-5627-4E74-840C-217BA72297E6

Q44450066-901DE88C-C809-4625-BE05-6B63E92E03C5

Q44450066-BFBC36F2-F0C1-4D52-94E8-3B3AEC5DAA81

Q44450066-E34AF52C-B632-48F8-A7B6-757A9E9C7801

Q44450066-F81B8B28-E48F-4A69-919B-F8F9A8AE1E35

P2860

Q44450066-07198152-6C0B-470D-BD8B-9C925671EACA

Q44450066-181AD0C3-4296-4C24-A1CA-C95F005F7E99

Q44450066-1A466158-528A-4469-9530-539C1396B4A3

Q44450066-276EE3FD-7026-417C-A234-A9A2611D77E6

Q44450066-3254CCC6-4738-4DA3-B395-730340CE3BD2

Q44450066-50221825-F100-40E1-9E83-1D214D190871

Q44450066-532B1303-AC5D-4D06-AB01-E2DE6D8D4253

Q44450066-5E19F450-3F8A-4FC2-9EE1-DAF4251B829F

Q44450066-625A72DB-0582-4342-903A-286812C41E23

Q44450066-9105EEDD-1447-44E5-BD91-77E614AA4C8D

P2888

Q44450066-DFAA93D5-35E3-4085-BDD3-3021FA2023B8

P304

Q44450066-0CC4A0B9-0900-48B8-8590-D5A03BDB581D

P31

Q44450066-ACC5ADD4-E9C8-4D53-9E97-5F60AE7C1249

P356

Q44450066-BE4243B8-8B55-4A9E-99E4-A01DB4D24AB1

P407

Q44450066-CA531225-0002-4D4D-AB1A-E3AE285047C8

P433

Q44450066-776E7441-E445-45DD-8B6A-E88976E414E6

P478

Q44450066-BB5FB5A6-9AC5-4E95-8C0D-A92E8C79CE57

P50

Q44450066-6575E068-D4E9-4047-B227-7AA41239881D

P577

Q44450066-67CBA4D0-5320-4C97-B693-6FB91BA3B3F3

P5875

Q44450066-8FDBAD63-379D-4469-A6A8-656954177007

P698

Q44450066-A6D5822C-23DA-48B7-A8DF-891CCAF8D908

P921

Q44450066-46028ABC-124D-405D-ACE6-4D325215352E

Q44450066-56C3DAA5-F4E5-4150-A08F-7BCE3449F4ED

P356

P1433

P1476

HER2/PI-3K/Akt activation lead ...... an breast adenocarcinoma cells

@en

P2093

Christiane Knuefermann

http://www.w3.org/2001/XMLSchema#string

Gordon B Mills

http://www.w3.org/2001/XMLSchema#string

John Mendelsohn

http://www.w3.org/2001/XMLSchema#string

Ke Liang

http://www.w3.org/2001/XMLSchema#string

Ling Wu

http://www.w3.org/2001/XMLSchema#string

Mathias Schmidt

http://www.w3.org/2001/XMLSchema#string

Weidong Jin

http://www.w3.org/2001/XMLSchema#string

Yang Lu

http://www.w3.org/2001/XMLSchema#string

Zhen Fan

http://www.w3.org/2001/XMLSchema#string

P2860

Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor

Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA

Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase

NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling

Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt

Regulation of cell death protease caspase-9 by phosphorylation

Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN

The protein kinase B/Akt signalling pathway in human malignancy

P2888

P304

3205-3212

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.ONC.1206394

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

P577

2003-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10747100

http://www.w3.org/2001/XMLSchema#string

P698

12761490

http://www.w3.org/2001/XMLSchema#string

P921

multiple drug resistance